跳至主要内容
临床试验/NCT00977873
NCT00977873已完成2 期

Randomised, Multi-Centre, Double-Blind, Placebo-Controlled Trial of Vitamin D Supplementation in Patients With Chronic Obstructive Pulmonary Disease

Barts & The London NHS Trust7 个研究点 分布在 1 个国家目标入组 240 人开始时间: 2009年9月最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
240
试验地点
7
主要终点
Time to first moderate / severe COPD exacerbation

研究概览

简要总结

The study null hypothesis is that vitamin D supplementation will not influence time to upper respiratory tract infection or time to moderate/severe exacerbation of chronic obstructive pulmonary disease.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
40 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Medical record diagnosis of COPD, emphysema or bronchitis
  • Post-bronchodilator FEV1 / FVC < 70% or post-bronchodilator FEV1 / slow VC < 70%
  • Post-bronchodilator FEV1 < 80% predicted
  • Age ≥ 40 years on day of first dose of IMP
  • Smoking history ≥ 15 pack-years
  • If a woman of child-bearing potential, is sexually abstinent or has negative pregnancy test within 7 days of recruitment and agrees to use reliable form of contraception until she has completed the study
  • Able to give written informed consent to participate

排除标准

  • Current diagnosis of asthma
  • Known clinically significant bronchiectasis
  • Known sarcoidosis, hyperparathyroidism, nephrolithiasis, active tuberculosis, vitamin D intolerance, liver failure, renal failure, terminal illness, lymphoma or other malignancy not in remission for ≥ 3 years
  • Taking benzothiadiazine derivative, cardiac glycoside, carbamazepine, phenobarbital, phenytoin or primidone
  • Taking dietary supplement or topical preparation containing vitamin D up to 2 months before first dose of IMP
  • Treatment with any investigational medical product or device up to 4 months before first dose of IMP
  • Breastfeeding, pregnant or planning a pregnancy
  • Baseline corrected serum calcium > 2.65 mmol/L
  • Baseline serum creatinine > 125 micromol/L

结局指标

主要结局

Time to first moderate / severe COPD exacerbation

时间窗: One year

Time to first upper respiratory tract infection

时间窗: One year

次要结局

  • Time to unscheduled health service use for upper respiratory tract infection or moderate / severe exacerbation of chronic obstructive pulmonary disease(One year)
  • Proportion of participants experiencing hypercalcaemia(One year)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (7)

Loading locations...

相似试验

Trial of Vitamin D Supplementation in Chronic... | 临床试验